<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794167</url>
  </required_header>
  <id_info>
    <org_study_id>CISL 12-05</org_study_id>
    <nct_id>NCT03794167</nct_id>
  </id_info>
  <brief_title>BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma</brief_title>
  <acronym>CISL</acronym>
  <official_title>Randomized Phase II Multi-center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan as Conditioning Therapy for Autologous Stem-cell Transplantation(ASCT) in Patients With Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soonchunhyang University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators developed a protocol comparing busulfan/cyclophosphamide/etoposide (BuCE)
      and busulfan/melphalan/etoposide (BuME) regimen as a conditioning for high-dose therapy (HDT)
      in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous busulfan containing regimens as conditioning regimen have been used for both
      allogeneic and autologous stem cell transplantation in patients with hematologic and
      non-hematologic malignancies.

      The investigators have previously studied that conditioning regimen of i.v.
      busulfan/melphalan/etoposide (BuME) was well tolerated and effective in patients with
      relapsed or high risk NHL. And busulfan/cyclophosphamide/etoposide (BuCE) conditioning
      regimen has been extensively utilized in ASCT for NHL.

      Therefore, based on the encouraging results, the investigators will conduct a randomized
      phase II multicenter trial of BuCE versus BuME as conditioning therapy for ASCT in patients
      with NHL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2012</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>calculate from the date of ASCT until the time of disease progression, relapse, or death calculate from the date of ASCT until the time of disease progression, relapse, or death calculate from the date of ASCT until the time of disease progression, relapse, or death Calculate from the date of ASCT (autologous stem cell transplantation) until the time of disease progression, relapse, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>calculate from the date of ASCT until the time of death from any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of regimen related toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>calculate toxicities frequency</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>busulfan cyclophosphamide etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>busulfan melphalan etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6</description>
    <arm_group_label>busulfan cyclophosphamide etoposide</arm_group_label>
    <arm_group_label>busulfan melphalan etoposide</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide 50mg/kg/day i.v. on days -3 and -2</description>
    <arm_group_label>busulfan cyclophosphamide etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>etoposide 400mg/m2 day i.v. on days -5 and -4</description>
    <arm_group_label>busulfan cyclophosphamide etoposide</arm_group_label>
    <arm_group_label>busulfan melphalan etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>melphalan 50mg/m2/day i.v. on days -3 and -2</description>
    <arm_group_label>busulfan melphalan etoposide</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed aggressive NHL

          2. Mantle cell lymphoma

          3. salvage chemotherapy sensitive relapse/refractory NHL or high risk NHL with remission
             in induction chemotherapy

          4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.

          5. Age; 18-65

          6. Adequate renal function: serum creatinine â‰¤ 1.5mg/dL

          7. Adequate liver functions: Transaminase (AST/ALT) &lt; 3 X upper normal value &amp; Bilirubin
             &lt; 2 X upper normal value

        Exclusion Criteria:

          1. low grade NHL

          2. Any other malignancies within the past 5 years except curatively treated non-melanoma
             skin cancer or in situ carcinoma of cervix uteri

          3. Other serious illness or medical conditions

               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months
                  prior to study entry

               -  History of significant neurological or psychiatric disorders

               -  Active uncontrolled infection (viral, bacterial or fungal infection)

          4. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          5. HIV (+)

          6. Patients who have hepatitis B virus (HBV) (+) are eligible. However, primary
             prophylaxis using antiviral agents (i.e. lamivudine) is recommended for HBV carrier to
             prevent HBV reactivation during whole treatment period -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong-Ho Won, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jong-Ho Won</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soonchunhyang University Hospital</investigator_affiliation>
    <investigator_full_name>Jong-Ho Won</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

